BioSpace News Archive

Retractable Technologies, Inc. (NYSE American: RVP) announced today that, in accordance with the 30 day notice requirement, it received a preliminary notice from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness & Response (“HHS/ASPR”) expressing its intent to exercise at least the first two one-month options under the February 2021 contract between HHS/ASPR and Retractable

Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announced that it will host a key opinion leader (KOL) webinar on ABX464 for the treatment of ulcerative colitis (UC).

Hoag Family Cancer Institute announced the opening of two additional molecular imaging and therapy trials, the first to be offered in Orange County and in the United States.

While cardiovascular disease remains the leading cause of death globally, new research led by NYU Grossman School of Medicine and Moi University School of Medicine found that addressing and incorporating social determinants of health in the clinical management of blood pressure in Kenya can improve outcomes for patients with diabetes or hypertension.

MyoStrain provided a uniquely sensitive and reproducible measure of segmental heart function to help physicians quantify differences in heart failure patients and risk-stratify patient populations based on the individual extent and severity of dysfunction

Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced it will release financial results for the first quarter 2021 after market close on May 12, 2021

ASG Superconductors with Helmholtz-Zentrum Dresden-Rossendorf (HZDR) will build the world’s first prototype that tracks moving tumors with magnetic resonance imaging (MRI) in real time during proton therapy, combining a rotating open MRI device for the LINAC-MR system Alberta Health Services, with an actively scanned clinical-akin proton beam at OncoRay, the Dresden-based National Center for Radiation Research in Oncology.

Researchers at the Institute of Bioelectronic Medicine at The Feinstein Institutes for Medical Research developed a long-term implant model for vagus nerve stimulation (VNS) in mice that successfully modulates heart rate and inflammatory proteins. The device and procedure may change the way preclinical bioelectronic medicine research is conducted and lead to alternative therapies for various chronic diseases, includ

Himalaya Therapeutics (“Himalaya”), which are based on the Conditionally Active Biologics (“CAB”) technology platform, today announced the appointment of Nicholas Desjardins as chief financial officer and corporate development officer.

Novamind Inc., a leading mental health company specialized in psychedelic medicine, will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.